ImCheck Therapeutics
- Company typePrivate
- Founded2017
- HeadquartersMarseille, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
ImCheck Therapeutics firmographics
Firmographics- Name
- ImCheck Therapeutics
- Legal name
- ImCheck Therapeutics
- Website
- https://imchecktherapeutics.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
ImCheck Therapeutics industry classification
Industry- Product category
- Cancer Immunotherapy Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where ImCheck Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Marseille
- HQ country
- France
- HQ region
- Europe
Markets served
ImCheck Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Marketing channels3 records
ImCheck Therapeutics product offering
Product offeringCore offering
ImCheck Therapeutics designs and develops first-in-class immunotherapeutic monoclonal antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules to selectively activate γ9δ2 T cells. Its lead candidate ICT01 is a humanized anti-BTN3A antibody for immuno-oncology indications including acute myeloid leukemia and solid tumors, while ICT41 extends the same γ9δ2 activation mechanism to infectious diseases. The company is clinical-stage and pre-revenue, focused on advancing its pipeline through regulatory and clinical milestones.
Product overview
ImCheck Therapeutics is developing a pipeline of novel immunotherapeutic antibodies targeting butyrophilins (BTN) and BTN-like (BTNL) molecules. The core products are ICT01 and ICT41, both anti-BTN3A monoclonal antibodies that selectively activate γ9δ2 T cells. ICT01 focuses on immuno-oncology applications for solid tumors and hematologic malignancies, while ICT41 targets infectious diseases. The company is leveraging its proprietary understanding of butyrophilin biology to create a diversified pipeline with first-in-class therapeutic potential.
Differentiator
Problem solved
Functional benefit
Products and services
- ICT01 ICT01 is a humanized, anti-BTN3A (CD277) monoclonal antibody that selectively activates γ9δ2 T cells for immuno-oncology applications. It promotes tumor cell recognition and elimination by activating the anti-tumor immune response, leading to γ9δ2 T-cell migration from circulation into tumor tissue and secretion of pro-inflammatory cytokines (IFNγ, TNFα). ICT01 is being developed for acute myeloid leukemia (AML), solid tumors (melanoma, urothelial cell carcinoma, head and neck squamous cell carcinoma, ovarian cancer), and hematologic malignancies, including patients ineligible for intensive chemotherapy and TP53-mutated AML. ICT01 has received FDA Fast Track Designation (September 2024) and Orphan Drug Designation from both the FDA and EMA (July 2025).
- ICT41 ICT41 is a humanized, anti-BTN3A monoclonal antibody that selectively activates γ9Vδ2 T cells for the treatment of infectious diseases. Once activated, these cells orchestrate a broad immune response through multiple pathways involving granulocytes, CD8 T cells, and NK cells capable of combatting viral, bacterial/mycobacterial, and parasitic infections. ICT41 is currently in proof-of-concept preclinical studies.
Quantifiable outcome
- 96% composite complete remission (CRc) rate and 74% complete remission (CR) in newly diagnosed AML patients treated with ICT01 + azacitidine + venetoclax
- +4 more outcomes
Companies that use ImCheck Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
ImCheck Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ImCheck Therapeutics partnerships and signals
Strategic signalRecent moves7 records
Expansion highlights5 records
ImCheck Therapeutics competitors and assessment
Company assessmentDirect peers
- Innate Pharma: French immuno-oncology company also headquartered in Marseille, developing antibody-based therapeutics leveraging innate immune cells including γδ T cells. Most directly comparable peer given overlapping geography, modality, and γδ T-cell biology focus.
- Adaptimmune: Clinical-stage cell therapy company developing engineered T-cell receptor (TCR) therapies for solid tumors, with overlapping focus on T-cell receptor biology and cancer immunotherapy, though using cell therapy rather than antibody modality.
- MacroGenics: Clinical-stage biotech developing monoclonal antibody therapeutics for cancer, including bispecifics and antibody-drug conjugates. Comparable as a fellow antibody-focused oncology biotech with multiple clinical-stage programs.
- CytomX Therapeutics: Clinical-stage oncology biotech developing antibody-based therapeutics (Probody platform) for cancer, with similar modality, clinical-stage profile, and combination therapy focus in immuno-oncology.
Broad incumbents
- Genmab: Established antibody-focused biotech with broad oncology pipeline including approved bispecifics (Epkinly). Comparable antibody platform approach but broader, more mature, and commercial-stage versus ImCheck's clinical-stage focus.
- AstraZeneca: Global pharmaceutical leader with deep oncology franchise including checkpoint inhibitor Imfinzi and ADC Enhertu. Comparable as a major oncology player whose checkpoint inhibitor and ADC franchises compete in ImCheck's combination therapy landscape.
- Servier: French-headquartered global pharmaceutical company with significant oncology presence including hematology assets. Comparable as a French-headquartered major pharma player active in ImCheck's target indications and geographic ecosystem.
Emerging players
- Iovance Biotherapeutics: Commercial-stage cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for cancer. Comparable as a T-cell focused oncology player, though ImCheck's γδ T-cell approach is mechanistically distinct.
- Compugen: Clinical-stage immuno-oncology company developing antibody-based therapeutics with focus on novel immune targets. Comparable as a fellow clinical-stage biotech pursuing innovative immuno-oncology mechanisms.
- Pieris Pharmaceuticals: Clinical-stage biotech developing proprietary anticalin-based protein therapeutics for cancer and respiratory disease. Comparable as a smaller clinical-stage biotech with proprietary protein-engineering platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
ImCheck Therapeutics social profiles
Digital presenceImCheck Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ImCheck Therapeutics leadership team
Management profileNumber of profiles
Profiles8 records
ImCheck Therapeutics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors20 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ImCheck Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ImCheck Therapeutics
What does ImCheck Therapeutics do?
ImCheck Therapeutics designs and develops first-in-class immunotherapeutic monoclonal antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules to selectively activate γ9δ2 T cells. Its lead candidate ICT01 is a humanized anti-BTN3A antibody for immuno-oncology indications including acute myeloid leukemia and solid tumors, while ICT41 extends the same γ9δ2 activation mechanism to infectious diseases. The company is clinical-stage and pre-revenue, focused on advancing its pipeline through regulatory and clinical milestones.
Is ImCheck Therapeutics a public or private company?
ImCheck Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was ImCheck Therapeutics founded?
ImCheck Therapeutics was founded in 2017. It employs 11 to 50 people.
Where is ImCheck Therapeutics based?
ImCheck Therapeutics is headquartered in Marseille, France, in the Europe region.
Who are ImCheck Therapeutics's main competitors?
Direct peers on record are Innate Pharma, Adaptimmune, MacroGenics and CytomX Therapeutics. Broad incumbents are Genmab, AstraZeneca and Servier. Emerging players are Iovance Biotherapeutics, Compugen and Pieris Pharmaceuticals.
Does ImCheck Therapeutics have an API?
No public API is recorded for ImCheck Therapeutics.
What industry is ImCheck Therapeutics in?
ImCheck Therapeutics's product category is Cancer Immunotherapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.